Search results for "Cor Malalties"

showing 10 items of 20 documents

Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney dis…

2021

Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls. Methods: We evaluated 2445 CKD patients (2010–2012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laborator…

MaleNephrologymedicine.medical_specialtyAutosomal dominant polycystic kidney diseaseRenal functionComorbiditylcsh:RC870-923urologic and male genital diseasesCarotid Intima-Media ThicknessAsymptomaticNephropathyAutosomal dominant polycystic kidney diseaseInternal medicineChronic kidney diseasemedicineHumansAnkle Brachial Indexcardiovascular diseasesRenal Insufficiency ChronicProteinuriabusiness.industryMiddle AgedPolycystic Kidney Autosomal DominantPrognosislcsh:Diseases of the genitourinary system. Urologymedicine.diseaseCardiovascular diseasePlaque Atheroscleroticfemale genital diseases and pregnancy complicationsNephropathyCor MalaltiesBlood pressureCardiovascular DiseasesHeart Disease Risk FactorsNephrologyDisease ProgressionInsuficiència renal crònicaFemalemedicine.symptombusinessResearch ArticleKidney disease
researchProduct

Mortality and cardiovascular disease burden of uncontrolled diabetes in a registry-based cohort: the ESCARVAL-risk study

2018

Background: Despite the epidemiological evidence about the relationship between diabetes, mortality and cardiovascular disease, information about the population impact of uncontrolled diabetes is scarce. We aimed to estimate the attributable risk associated with HbA1c levels for all-cause mortality and cardiovascular hospitalization.Methods: Prospective study of subjects with diabetes mellitus using electronic health records from the universal public health system in the Valencian Community, Spain 2008–2012. We included 19,140 men and women aged 30 years or older with diabetes who underwent routine health examinations in primary care.Results: A total of 11,003 (57%) patients had uncontrolle…

Malelcsh:Diseases of the circulatory (Cardiovascular) systemTime Factors030204 cardiovascular system & hematologyPatient Admission0302 clinical medicineRisk FactorsCause of DeathEpidemiologyattributable riskElectronic Health RecordsProspective StudiesRegistries030212 general & internal medicineProspective cohort studyStrokediabetesDiabetesMiddle AgedPrognosisAll-cause mortalitystrokeCor MalaltiesHospitalizationCoronary heart diseaseStrokeCardiovascular DiseasesCohortall-cause mortalityFemaleAttributable riskCardiology and Cardiovascular MedicinehospitalizationResearch ArticleAdultmedicine.medical_specialtyHbA1cRisk Assessment03 medical and health sciencesInternal medicineDiabetes mellitusDiabetes MellitusmedicineHumansHypoglycemic Agentscoronary heart diseaseDisease burdenAgedGlycated HemoglobinPrimary Health Carebusiness.industrymedicine.diseaselcsh:RC666-701SpainRelative riskAttributable riskbusinessBiomarkersBMC Cardiovascular Disorders
researchProduct

Inhibición de la proproteína convertasa subtilisina/kexina tipo 9 (PCSK9) en el tratamiento de la hipercolesterolemia.

2016

Se diapome de un nuevo grupo de fármacoshipocolesterolemiantes potentes y bien tolerados, para completar las opciones terapéuticas en sujetos de alto o muy alto riesgo cardiovascular, especialmente con hipercolesterolemia genética, que con el tratamiento habitual, estatinas y asociaciones con ezetimiba o resinas, no consigan llegar a los objetivos propuestos o en aquellos con intolerancia a estatinas y necesidad de disminuir los concentraciones de cLDL por su alto riesgo cardiovascular

MedicinaCor Malalties
researchProduct

Documento de consenso de la Sociedad Española de Arteriosclerosis sobre las indicaciones de los inhibidores de la PCSK9 [Consensus document of the Sp…

2016

La SEA ha consensuado unas indicaciones médicas para el uso de los inhibidores de la PCSK9 (tabla 1), atendiendo a la relación coste/beneficio, y teniendo en cuenta que aún no se dispone de datos sobre la protección de episodios cardiovasculares.

MedicinaCor Malalties
researchProduct

Perfil clínico de los pacientes tratados con evolocumab en unidades hospitalarias de nefrología en España

2021

Describir las características clínicas de los pacientes tratados con evolocumab, las razones del inicio de la terapia y los efectos del tratamiento en la fase inicial de disponibilidad de evolocumab en las unidades de nefrología de España.

NefrologiaMalalties cerebrovascularsCor Malalties
researchProduct

Insulin withdrawal in diabetic kidney disease : What are we waiting for?

2021

The prevalence of type 2 diabetes mellitus worldwide stands at nearly 9.3% and it is estimated that 20–40% of these patients will develop diabetic kidney disease (DKD). DKD is the leading cause of chronic kidney disease (CKD), and these patients often present high morbidity and mortality rates, particularly in those patients with poorly controlled risk factors. Furthermore, many are overweight or obese, due primarily to insulin compensation resulting from insulin resistance. In the last decade, treatment with sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have been shown to be beneficial in renal and cardiovascular targets; however…

Opinionmedicine.medical_specialtyinsulinHealth Toxicology and Mutagenesismedicine.medical_treatmentRenal function030209 endocrinology & metabolism030204 cardiovascular system & hematologyOverweight03 medical and health sciences0302 clinical medicineInsulin resistancecardiovascular diseaseInternal medicinemedicineHumansHypoglycemic AgentsInsulinDiabetic NephropathiesSGLT2iDiabetic kidney diseaseSodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsDiabetisbusiness.industryInsulinMortality ratePublic Health Environmental and Occupational HealthRType 2 Diabetes Mellitusmedicine.diseaseRepaglinideCardiovascular diseaseGLP-1RAdiabetic kidney diseaseCor MalaltiesDiabetes Mellitus Type 2Medicinemedicine.symptombusinessKidney diseasemedicine.drug
researchProduct

Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015

2017

BACKGROUND: The burden of cardiovascular diseases (CVDs) remains unclear in many regions of the world. OBJECTIVES: The GBD (Global Burden of Disease) 2015 study integrated data on disease incidence, prevalence, and mortality to produce consistent, up-to-date estimates for cardiovascular burden. METHODS: CVD mortality was estimated from vital registration and verbal autopsy data. CVD prevalence was estimated using modeling software and data from health surveys, prospective cohorts, health system administrative data, and registries. Years lived with disability (YLD) were estimated by multiplying prevalence by disability weights. Years of life lost (YLL) were estimated by multiplying age-speci…

Salut mundialEpidemiologiaMort CausesCor Malalties
researchProduct

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence

2021

Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addition to being used for glycemic control in diabetic patients, these drugs also have other favorable effects such as weight loss and lowering blood pressure, and more recently, they have been shown to have cardio and renoprotective effects with anti-inflammatory properties. Concerning the latter, the individual or associated use of these antihyperglycemic agents has been linked with a decrease in p…

SenescenceEndocrinology Diabetes and MetabolismAdipose tissueInflammationGlycemic ControlReview ArticleDiseaseBioinformaticsDiseases of the endocrine glands. Clinical endocrinologyGlucagon-Like Peptide-1 ReceptorProinflammatory cytokineEndocrinologySodium-glucose cotransporter 2 inhibitors (SGLT2i)Weight lossDiabetes mellitusmedicineHumansSodium-Glucose Transporter 2 InhibitorsCellular SenescenceGlycemicInflammationMetabolic SyndromeManagement of diabetesRonyonsDiabetisbusiness.industryRC648-665medicine.diseaseCor MalaltiesAdipose TissueantihyperglycemicPatients obesity and cardiorenal compromiseglycemic controlmedicine.symptombusinessGlucagon-like peptide 1 receptor agonists (GLP-1RA)
researchProduct

The conditioning of the trunk muscles and back health in Physical Education

2021

Background. The search for scientific arguments for the inclusion of back health as a fundamental aspect in the contents of physical conditioning for health in Physical Education (PE) in schools has led us to search for the relationship between the resistance of trunk musculature and non-specific low back pain in 1st year compulsory secondary education (CSE) students. Methods. Three tests were used: the front bridge (FB) test, the dominant side bridge (SB) test, and the modified Biering-Sorensen test (BS). The Nordic questionnaire was used to assess back health.Results. The prevalence of low back pain in boys was 58.3% (n = 42), while in girls it was 52.7% (n = 39) with no statistically sig…

medicine.medical_specialtyNon-specific low back painPhysical Therapy Sports Therapy and RehabilitationSecondary educationPhysical educationmuscular endurancesecondary educationmedicineEducación Física y Deportivahealth educationSalutCore (anatomy)business.industrycoreLow back painTrunkTest (assessment)Cor MalaltiesMuscular enduranceHealth educationSports medicinePhysical therapyConditioningpopulation characteristicsnon-specific low back painHealth educationCoreEducació secundàriamedicine.symptombusinessInclusion (education)RC1200-1245
researchProduct

The Sick Adipose Tissue: New Insights Into Defective Signaling and Crosstalk With the Myocardium

2021

Adipose tissue (AT) biology is linked to cardiovascular health since obesity is associated with cardiovascular disease (CVD) and positively correlated with excessive visceral fat accumulation. AT signaling to myocardial cells through soluble factors known as adipokines, cardiokines, branched-chain amino acids and small molecules like microRNAs, undoubtedly influence myocardial cells and AT function via the endocrine-paracrine mechanisms of action. Unfortunately, abnormal total and visceral adiposity can alter this harmonious signaling network, resulting in tissue hypoxia and monocyte/macrophage adipose infiltration occurring alongside expanded intra-abdominal and epicardial fat depots seen …

obesityEndocrinology Diabetes and MetabolismAdipokineAdipose tissueAdipose tissueMyocardiocytesInflammationContext (language use)ReviewBioinformaticsDiseases of the endocrine glands. Clinical endocrinologyCoronary artery diseasechemistry.chemical_compoundEndocrinologyAdipocytemicrobiotamedicineHumansMyocytes CardiacMyocardial infarctionObesityInflammationbusiness.industryMyocardiumMicrobiotaRC648-665medicine.diseaseCor MalaltiesmyocardiocytesAdipose TissuechemistryObesitatmedicine.symptombusinessDysbiosisSignal Transduction
researchProduct